Antidyslipidemics Market Forecast
The antidyslipidemic market is expected to fall to $18 billion in 2018. The decline will be driven by the deep genericization of the market, further exacerbated by the patent expiry of the top antidyslipidemic, Pfizer's Lipitor, as well as by the recent negative messages from the ENHANCE, SEAS and ARBITER 6 HALTS clinical trials.
View full press release